Double bond pharmaceutical
WebIgor Lokot Board member & Company President. Igor Lokot, born 1972, Member of the Board in Double Bond Pharmaceutical International AB since April 2015. Igor is President and Founder of Double Bond Pharmaceutical AB. Igor has a PhD in Bio-organic Chemistry and a wide experience in drug development. Igor is one of the founders of the ... WebNov 4, 2024 · About Double Bond Pharmaceutical AB (DBP): DBP is a Swedish pharmaceutical company founded in 2014 with the aim of developing and commercializing innovative products and methods for the treatment ...
Double bond pharmaceutical
Did you know?
WebDouble Bond Pharmaceutical International AB is a pharmaceutical company which develops and commercializes approaches for treatment of cancers, infections, autoimmune diseases and other life ... WebAt Double Bond Pharmaceutical, our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with … Our Products Our specialties are brain cancer, liver cancer, and pneumonia. … Our News Find out more about us in our news categories Press Releases, … Drugsson Drugsson is our own drug distribution company with its own … Post address: Virdings allé 32B, 75 450 Uppsala, Sweden Visiting address: … Pipeline In this section you will find current statistics on our products. Our drug for … Double Bond Pharmaceutical is a Swedish biotechnology company that specializes … Double Bond Pharmaceutical AB (DBP) has received Orphan Drug Designation from … The BeloGal® technology was developed by Double Bond Pharmaceutical and the … Press Releases All press releases about our company are published by …
http://doublebondeg.com/ WebMar 28, 2024 · Double Bond Pharmaceutical International AB is a manufacturer of pharmaceutical preparation. The company is located in Uppsala, Sweden. It develops medicinal products for patients suffering from diseases such as cancer, infla mmation, asthma or diabetes. View full business profile
WebApr 14, 2024 · Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential U.S. drug ... WebDec 3, 2015 · Double Bond Pharmaceutical AB (DBP) presents today an update regarding the clinical study on TEMODEX, the company's new asset in brain cancer treatment, which was used in combination with the standard treatment consisting of surgical resection, radiotherapy, and concomitant temozolomide therapy followed by adjuvant …
WebJun 12, 2024 · In October 2015, Double Bond Pharmaceutical acquired the rights to Temodex - a drug registered in Belarus for the treatment of brain tumors. In July 2016, the company was granted Orphan Drug Designation status by EMA for Temodex. (C) 2024 Electronic News Publishing, source ENP Newswire. All news about DOUE BOND:
WebPipeline In this section you will find current statistics on our products. Our drug for the treatment of brain and liver cancer has received (*) Orphan Drug Designation from the EMA. SI-053 (brain tumor) Discovery fieldglass lmWebDouble Bond Pharmaceutical is a fast growing pharmaceutical company which develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases ... fieldglass kforceWebPress Releases All press releases about our company are published by Spotlightstockmarket on their website. You can also download and read our archive news. Visit ... fieldglass linkWebDouble Bond Pharmaceutical International AB is a pharmaceutical company which develops and commercializes approaches for treatment of cancers, infections, … fieldglass lmcoWebSummary Double Bond Pharmaceutical International AB (DBP) is a pharmaceutical company that develops and commercializes treatment of autoimmune diseases, cancers, infections, and other life-threatening disorders. The company’s products include proprietary platforms SA-033, SI-053, SA-042, and SA-083. Its temozolomide is an active … fieldglass lockheedWebStock analysis for Double Bond Pharmaceutical International AB (DBPB:Spotlight) including stock price, stock chart, company news, key statistics, fundamentals and company profile. fieldglass login usWebApr 6, 2024 · Double Bond Pharmaceutical International AB is a pharmaceutical company, which engages in developing and commercializing approaches for treatment of … fieldglass job postings